Charts suggest that JNJ has further downside risk.
This sector is one of the few areas of the market where you'll find myriad compelling values.
AMGN is neutral now, but a close below $158 weakens the chart picture.
A close below $95 is likely to precipitate further short-term declines.
If you control your risk, then the returns will come.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
The highly elusive Cleveland Research is putting the screws to Fitbit.
'If there are worries about the market topping out it isn't evident in [today's] price action.'
Brexit concerns pummel the pound while Alphabet gets set to unveil several new devices.

Columnist Conversations

It was just about 16 years ago in 2001 when AOL shocked the world and announced buying entertainment giant Tim...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.